Login to Your Account

FDA's Next Northera Demand? We Chelsea; Phase III Hits Goal

By Randy Osborne
Staff Writer

Thursday, December 6, 2012

Chelsea Therapeutics Inc.'s primary endpoint-hitting Phase III news about Northera (droxidopa) sent the stock south, as Wall Street reacted to word that effects on dizziness – the main goal of the trial – did not last as long as the FDA may want for approval.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription